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John Mann,a Peter W. Taylor,a Colin R. Dorgan,b Peter D. Johnson,b
Francis X. Wilson,b Richard Vickers,b Aaron G Dalea and Stephen Neidle*a
Academic drug discovery is playing an increasingly important role in the identification of new therapies for
a wide range of diseases. There is no one model that guarantees success. We describe here a drug
discovery story where chance, the ability to capitalise on chance, and the assembling of a range of
expertise, have all played important roles in the discovery and subsequent development of an antibiotic
chemotype based on the bis-benzimidazole scaffold, with potency against a number of current therapeuti-
cally challenging diseases. One compound in this class, SMT19969, has recently entered Phase 2 human
clinical trials for the treatment of Clostridium difficile infections.The background
The Neidle laboratory, which from 1986–2002 was at the
Institute of Cancer Research in the UK (ICR), has long been
involved in the study of small molecule–nucleic acid interac-
tions, and in the use of X-ray crystallography and molecular
modelling for the rational design of sequence- and structure-oyal Society of Chemistry 2015
Taylor has spent a large
f his career in Big Pharma
is currently Professor of
biology at UCL. His
ch interests involve novel
aches to the treatment of
ous disease, with a focus
e development of anti-
ial therapeutics that sup-
or abrogate the emergence
g resistant variants or com-
se the virulence properties
stemic pathogens such as
cillin-resistant staphylococci
ative agent of inhalation
en Escherichia coli K1. He
ht on the fitness of patho-
ce vessels.
Med. Chem. Commun., 2015, 6, 1420–1426 | 1421This journal is © The Royal Society of Chemistry 2015
Colin Dorgan
Colin Dorgan graduated with a
first class MChem from the Uni-
versity of Liverpool in 2005. As
part of the course he took a 12
month placement at Pfizer PGRD
and upon completion of his
undergraduate studies he
returned to the drug discovery
industry working for Summit Plc.
He undertook research in several
therapeutic areas and most nota-
bly contributed to the discovery
of 2 clinical candidates; Utrophin
upregulator C1100 for Duchenne
Muscular Dystrophy and antibiotic SMT019969 for C. Difficile
infections. He now works outside of the drug discovery industry for
Carbosynth Ltd in Oxfordshire, UK.
Pete Johnson
Pete Johnson completed his DPhil
in Organic Chemistry at the Uni-
versity of Oxford in 2004. He
spent a year as a Research Associ-
ate at the University of Chicago
before returning to the UK and
joining Summit (then VASTox) in
2005. Research work over four
years covered the design of mole-
cules to upregulate utrophin for
the treatment of DMD, and two
antibiotic programs including the
use of bis-benzimidazoles for treat-
ment of CDAD. Since 2009 he has
worked for Evotec Ltd. in the field of neurodegenerative disorders.
Francis Wilson
Francis Wilson is Director of
Chemistry at Summit Therapeu-
tics. He has been involved in
drug discovery for over 30 years
working in a wide range of ther-
apeutic areas. At Summit he has
played leading roles in the dis-
covery and early development of
a number of clinical candidates,
including SMT C1100 for treat-
ment of Duchenne muscular dys-
trophy and SMT19969 for the
treatment of C. Difficile infec-
tion. He was formerly Director
of Chemistry at Cellzome, prior to which he worked with Xenova
and Roche, and has authored/co-authored over 100 patents and
publications.
Richard Vickers
Richard Vickers completed his
PhD from Reading University
before undertaking postdoctoral
studies with Professor Steve
Davies, and taking up a stipendi-
ary lectureship at St Catherine's
College, at the University of
Oxford. He is currently CSO —
Antimicrobials at Summit Thera-
peutics, a UK based biotech com-
pany focused on the develop-
ment of agents in areas of high
unmet medical need. His
research interests are in the
development of new antimicrobial having worked on novel agents
for tuberculosis, a project that was partnered with the Eli-Lilly TB
Drug Discovery Initiative, and more recently on the development
of agents to treat C. difficile infections.
Aaron Dale
Aaron Dale (www.twitter.com/
NotDrDalePhD) is a graduate-
entry medicine student at Oxford
University. He holds a PhD in
drug discovery from University
College London for work on the
symmetric bis-benzimidazole series
of compounds and has carried out
post-doctoral research into small
molecule inhibitors of the hypoxia
inducible factor pathway. His
research interests include develop-
ment of novel antimicrobial and
anti-cancer agents, and the use of
evidence-based medicine in patient care. He is a keen cyclist and
drummer for the Klezmer group Black Shabbat.
Stephen Neidle
Stephen Neidle received his under-
graduate and graduate education
at Imperial College London. He is
Professor of Chemical Biology in
the School of Pharmacy, Univer-
sity College London, where he has
also served as Director of
Research. Previously he was Pro-
fessor of Biophysics at the Institute
of Cancer Research UK, where he
was also Dean (1997–2002). His
research interests focus on the dis-
covery and development of novel
nucleic acid-targeted small mole-
cules of potential use in the treatment of those human cancers, neuro-
degenerative disorders and infective diseases that are of most unmet
clinical need.
MedChemComm Review
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
1 
Ju
ly
 2
01
5.
 D
ow
nl
oa
de
d 
on
 2
1/
01
/2
01
6 
16
:0
6:
47
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
MedChemCommReview
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
1 
Ju
ly
 2
01
5.
 D
ow
nl
oa
de
d 
on
 2
1/
01
/2
01
6 
16
:0
6:
47
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinerecognition agents. In the late 1980s Neidle and his col-
leagues had started on a programme of X-ray analyses of
complexes between double-helical oligonucleotides and small
molecules that were known to bind in the minor groove of
B-form DNA. Many of these compounds were well-established
to have biological activity, especially as anti-infective and
anti-parasitic agents. From 1990 onwards a number of crystal
structures of DNA complexes involving for example, the bis-
(phenyl amidinium) triazene compound berenil,1,2 the analo-
gous aliphatic-linked compound pentamidine3 and the bis-
benzimidazole Hoechst 33258,4 had been determined with a
PhD student, David Brown (later at Pfizer UK, now at the Uni-
versity of Kent) and a senior post-doctoral associate, Mark
Sanderson, (now at King's College London), both playing
prominent roles. Much of this structural work was (and still
is) in close collaboration5,6 with David Wilson and David
Boykin (Georgia State University, USA), who have pioneered
the medicinal chemistry-led discovery and development of
low-molecular-weight minor-groove binding compounds for
the treatment of infective diseases. Their work on tropical
parasitic diseases such as trypanosomiasis has resulted in
one such compound entering advanced clinical trials.7
Earlier crystallographic studies of the dipyrrolic polyamide
natural product netropsin by Richard Dickerson and col-
leagues8 at UCLA had shown that its binding to AT-rich
regions of duplex DNA was in the minor groove. Importantly
the convex shape of netropsin complemented the concave
surface of the groove, giving rise to the concept of isohelicity9
to describe the recognition of AT-rich narrow minor groove
DNA sequences. Isohelicity suggests that a particular radius
of curvature for the ligand is required in order for optimal
binding to take place. However combined biophysical and
crystallographic studies had shown that this is not necessar-
ily the case since a water molecule can bridge between an
amidinium group and a base edge in the groove even if the
ligand itself has a linear or near-linear shape.10
The crystal structures being determined in the Neidle lab-
oratory were being used as starting-points in several qualita-
tive and semi-quantitative molecular modelling studies with
the initial intent of rationalising patterns of ligand-DNA
hydrogen bonding and deciphering the role of water mole-
cules in the recognition process.11,12 Around this time, sev-
eral chemistry-based groups, most prominently that of Peter
Dervan at CalTech, were developing chemical ways of
recognising increasingly long sequences of duplex DNA, ulti-
mately as gene targeting agents.13 This approach uses the
concept of stringing together simple small building-blocks,
(mostly amido-substituted small heterocyclics which could
recognise individual bases by hydrogen-bonding to base
edges in the minor groove), into larger polyamide molecules,
some of which can recognise more than a complete turn of
duplex DNA. The approach has subsequently been extremely
successful and is now capable of selective recognition of indi-
vidual genes within a genome such that it is now being stud-
ied in animal models as a potential direct therapy for down-
regulating the expression of deleterious genes driving a1422 | Med. Chem. Commun., 2015, 6, 1420–1426particular disease state (see for example, a description of
targeting the estrogen receptor element in cells and
in vivo14). The Neidle group was interested in exploiting its
accumulated structural information in an analogous manner,
and to using parts of these established minor-groove binding
compounds as recognition building-blocks. Typical com-
pounds studied at that time included a number of
diamidines such as berenil and pentamidine, the asymmetric
bis-benzimidazole DNA stain Hoechst 33258 and symmetric
furan-based bis-diamidines from the Boykin/Wilson
laboratory.
A chance meeting
John Mann and his group (then at the University of Reading)
had collaborated with the Neidle group on a number of occa-
sions, primarily in their work with Michael Jarman and his
chemistry group at ICR, directed towards new anticancer
agents, such as inhibitors of the enzyme aromatase as poten-
tial drugs for the treatment of hormone-dependent breast
cancer.15 A totally unexpected meeting of the Mann and
Neidle families took place in the supermarket of the small
Tuscan town of Montaione in August 1990, when both fami-
lies were on their summer vacations and chemistry was far
from everyone's mind.16 This led to the families meeting
together at a local pizzeria, then inevitably to chemical dis-
cussions over drinks, and followed by the resolve to develop
a common project together.
Crystal structures had provided structural knowledge of
the minor groove binding for the well-studied asymmetric
bis-benzimidazole compound Hoechst 33258.4,17 We decided
that since the benzimidazole group was also a well-
established pharmacophore with drug-like attributes, it was a
suitable scaffold for our joint studies, which were aimed at
eventually developing a non-polyamide approach to the rec-
ognition of long DNA sequences (perhaps up to 12 base
pairs). Molecular modelling used the Hoechst 33258-
dĲCGCAAATTTGCG)2 complex crystal structure as a starting-
point. The application of simple steric principles (by ensur-
ing that there were no non-bonded close contacts at less than
van der Waals separation between the joined-up benzimid-
azole units and atoms in the DNA minor groove) led to the
concept of linking two benzimidazole units in a head-to-head
symmetric manner, which was predicted to have the comple-
mentary shape needed for effective AT base recognition. The
modelling indicated that this would be distinct from Hoechst
33258, would recognise four contiguous AT base pairs, and
chemical functionality would be achieved via para substitu-
tion on a phenyl ring directly attached to each benzimidazole
group.
After the summer break, the Mann group embarked on
the synthesis of the new series of bis-benzimidazoles (termed
BBZs) suggested by the modelling, which had not been previ-
ously reported in the literature, and this research continued
uninterrupted until 2008, firstly at the University of Reading
and later at Queen's University Belfast. The initial series ofThis journal is © The Royal Society of Chemistry 2015
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View Article Onlinecompounds were prepared18 by a very able Ghanaan PhD stu-
dent, Yaw Oboku-Boahen, through the oxidative condensa-
tion between 3,3′,4,4′-tetraaminobiphenyl and various simple
4-substituted aromatic aldehydes (e.g. 4-methoxy and
4-hydroxy). This reaction (Scheme 1) required heating the
compounds in nitrobenzene at 150 °C for 8–10 hours and
although the required bis-benzimidazoles were obtained the
yields were 25–40% at best. Although the yields were
improved by a French PhD student, Anne Baron, thus
allowing initial biological evaluation to be carried out, a new
milder method was required to provide greater quantities of
products. This was discovered and optimised by two excellent
postdoctoral fellows, Xiao-Wen Sun and Christine Le
Sann.19,21 This involved treating the tetraamine and aryl alde-
hydes in DMF with the oxidant Oxone at room temperature
and typical reaction times of 18 hours. With this reaction
method even complex bis-benzimidazoles such as a
chlorambucil mustard derivative could be prepared in yields
of up to 80%.
Once a number of substituted BBZs became available, a
technical officer (Emma Rayner), and two PhD students (IanThis journal is © The Royal Society of Chemistry 2015
Scheme 1Simpson and Eric Johansson) in the Neidle group undertook
crystallographic studies of the bis-Ĳ3″-hydroxy) and bis-Ĳ3″-
dimethylamino-1″-propyloxy) derivatives (Scheme 1), bound
to dodecanucleotide DNA duplexes (Protein Data Bank ids
453D and 1FTD).18,20 The prediction of four base-pair recog-
nition was verified by these crystallographic studies as well as
by DNA foot-printing studies conducted by Keith Fox (Univer-
sity of Southampton). Studies by the late Lloyd Kelland (ICR)
and John Hartley (University College London) showed that
several compounds in the series showed sub-μM inhibition
of cell growth in a panel of ovarian cancer cell lines, with the
bis-Ĳ3″-dimethylamino-1″-propyloxy) derivative being the most
active whereas substituents with uncharged and more hydro-
phobic end-groups resulted in a loss of activity.20,21 The bis-
Ĳ3″-dimethylamino-1″-propyloxy) derivative showed some
modest anti-tumour activity in human cancer xenograft
models,20 although this was insufficient to convince external
funders. The anti-cancer project was finally put on hold in
2006, even though a patent had been granted to Stephen
Neidle and John Mann in 2003 (ref. 22) in respect of the
potential anticancer activity of BBZs.
Microbiological studies
Although both the Neidle and Mann laboratories were then
largely focussed on other projects, subsequent events
resurrected the BBZ area. Stephen Neidle had moved his
group to the School of Pharmacy in London during 2002 and
by 2003/4 had started discussing a possible collaboration
with his microbiologist colleague Peter Taylor.
Peter Taylor had joined the School of Pharmacy in Novem-
ber 1998 after a long period in commercial drug discovery
and development. He established a team at the School dedi-
cated to the discovery of new compounds and novel therapeu-
tic modalities for the treatment of life-threatening systemic
infections caused by multidrug resistant pathogens such as
methicillin resistant Staphylococcus aureus (MRSA), vancomy-
cin resistant enterococci (VRE) and drug resistant Mycobacte-
rium tuberculosis (MDR-TB).
The discussions between Peter Taylor and Stephen Neidle
about the BBZ compounds culminated in a suggestion that
they might conceivably be inhibitors of bacterial gyrase
enzymes, so a preliminary evaluation was undertaken of two
BBZs against a selection of medically important bacterial
clinical isolates. This work was undertaken by Diana Lisa
Ramos Francisco, a Portuguese undergraduate gaining work
experience in London in 2003/4 under the European Erasmus
exchange programme. She found in early 2004 that com-
pounds CLS549 and CLS 260B possessed no significant
in vitro activity against Gram-negative bacteria such as
Pseudomonas aeruginosa, Proteus mirabilis and Klebsiella spe-
cies (strains responsible for many European and Stateside
cases of bacteraemia, septicaemia and wound infections) but
they elicited potent antibacterial effects against a range of
Gram-positive pathogens, including EMRSA-15 and EMRSA-
16 (representatives of two major MRSA clones isolated fromMed. Chem. Commun., 2015, 6, 1420–1426 | 1423
MedChemCommReview
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
1 
Ju
ly
 2
01
5.
 D
ow
nl
oa
de
d 
on
 2
1/
01
/2
01
6 
16
:0
6:
47
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article OnlineU.K. hospitals) and group A and group B streptococci. The
minimum drug concentrations required to prevent overnight
bacterial growth (MIC) against these Gram-positive bacteria
were impressive, ranging from 0.03–1 μg ml−1, and there was
no evidence of cross-resistance with any other group of anti-
bacterial agents – strongly suggestive of a novel mechanism
of antibacterial action.
This promising data led to two successful grant applica-
tions that provided an opportunity to assess the antibacterial
potential of a wider collection of BBZs. In 2007, an Academic
Excellence Award from the Royal Pharmaceutical Society,
achieved through national competition, enabled an investiga-
tion of the potency and antibacterial spectrum of activity of
these compounds. A Capacity Building Award from the Medi-
cal Research Council facilitated insights into the mode of
action of these putative drugs. A graduate student on the
Royal Pharmaceutical Society award, Joao Moreira, profiled
21 symmetric and asymmetric BBZs against a comprehensive
panel of Gram-positive clinical isolates, including ten from
the initial series synthesised by John Mann and co-workers.
This in-depth study23 confirmed the lack of activity against a
wide range of Gram-negative pathogens but established that
three compounds in particular possessed potent anti-
staphylococcal activity against four methicillin-susceptible S.
aureus and 61 MRSA strains from Peter Taylor's extensive
international collection of clinical isolates, with clinically
attractive MIC90 values (MIC required to inhibit 90% of the
isolates) in the sub-μg ml−1 range. Similar potent effects were
recorded against vancomycin intermediate-susceptible S.
aureus (VISA; clinically troublesome MRSA partially resistant
to the drug of last resort), Streptococcus pyogenes, Streptococ-
cus agalactiae and β-haemolytoc streptococci. Data from the
21 BBZ compounds facilitated a detailed understanding of
structure–activity relationships with respect to their anti-
staphylococcal activity. Encouragingly, the key compounds
displayed low cytotoxicity towards human fibroblasts and
were well-tolerated by zebrafish embryos following injection
into the yolk sac. A subsequent detailed investigation of the
anti-staphylococcal mode of action was undertaken by Aaron
Dale, a graduate student supported by the MRC funding. He
showed that BBZs, in common with many conventional, clini-
cally indispensable antibiotics, have a complex, multifactorial
antibacterial mechanism which includes the capacity to
inhibit the binding of DNA gyrase to DNA and to promote
the accumulation of single-stranded DNA breaks.24
Of particular interest was the relatively strong and previ-
ously unreported activity of several BBZs against Mycobacte-
rium tuberculosis (Mtb); this was manifest against both the
standard laboratory Mtb strain H37RV and 10:104, a recently
isolated drug-hetero-resistant Mtb bacterium. Further, the
compounds were active against logarithmic phase cultures
and latent cultures induced by hypoxia. This latter activity,
together with the fact that they were active against resistant
clinical isolates, suggested that they represent promising lead
compounds for development of an anti-Mtb agent active
against latent forms of the pathogen through a novel1424 | Med. Chem. Commun., 2015, 6, 1420–1426mechanism of action. Treatment of latent tuberculosis is a
vital component of elimination of the disease but is not effi-
ciently implemented with currently available drugs.
Summit entered the picture
John Mann's initial interactions with Summit Therapeutics
(www.summitplc.com) in 2007 resulted in an initial small-
scale project in which they independently agreed to evaluate
the MRSA activity of a set of BBZ compounds. This took place
soon after the first set of data became available from Peter
Taylor's laboratory, and involved outsourcing the screening
work to a contract research organisation (CRO), with Richard
Vickers leading the Summit activity. This new data set fully
confirmed the findings from the Taylor laboratory and at this
point all involved decided to work closely together and jointly
develop a strategy for the future development of the BBZ
compounds. A major early issue was the commercial poten-
tial of the MRSA activity. A patent granted in 1998 to Roche
in Basle with inventors Walter Häsler, Werner Leupin and
Yu-Hau Ji25 had come to light, which covered antibacterial
activity for a number of uncharged BBZs. Although the patent
focussed on E. coli, a few S. aureus strains were mentioned.
Summit undertook some medicinal chemistry in order to
attempt to improve on the existing activity and move into
novel chemical space. However it soon became apparent that
it would be more fruitful to focus on alternative bacterial tar-
gets, and Summit suggested in particular working on Clos-
tridium difficile infections. C. difficile is a serious hospital-
associated bacterial disease which especially affects the
elderly and is hard to treat with existing drugs. In 2011 it was
responsible for over 2000 deaths in the UK, and is estimated
to cause over 30 000 deaths in the USA. As the School of Phar-
macy was not initially set up to work on this pathogen, Sum-
mit commissioned C. difficile compound evaluation at several
CROs. Again potent activity was observed in several of the
uncharged initial BBZ compounds. Summit then embarked
on a comprehensive medicinal chemistry programme to opti-
mise activity with appropriate physicochemical properties.
The medicinal chemistry effort found that the structure–
activity requirements were exceptionally narrow and that sig-
nificant deviations from the original BBZ concept were not
tolerated in that the overall curvature and shape of the BBZ
scaffold are absolute requirements for retention of activity.
This work culminated in the discovery of the novel antibiotic
SMT19969,26 which is very closely related to the original BBZ
compounds invented by Stephen Neidle and John Mann, and
represents a fundamental repositioning of particular BBZ
compounds from generalised cell proliferation inhibitors to
targeted anti-infective agents. A subsequent Wellcome Trust
Seeding Drug Discovery funded project funded some further
chemistry, together with extensive animal and pre-clinical
toxicology work on the lead compound, with its biological
properties being characterized in collaboration with the
Neidle laboratory. Table 1 summarises anti-bacterial data for
three representatives of the early BBZ compounds, togetherThis journal is © The Royal Society of Chemistry 2015
Table 1 Antibacterial activities of selected BBZ compounds. The MIC90 values given here represents the MIC (the minimal inhibitory concentration of
compound) value at which ≥90% of the strains within a test population are inhibited; the 90th percentile. NA: data not available, for example on account
of solubility issues
Escherichia colia
Staphylococcus
aureusb Clostridium difficile
Mycobacterium tuberculosis
H37Rvc
NCTC10418 MC1061
ATCC
29213 EMRSA-16 CD630 R20291
(Logarithmic
phase)
(Hypoxia-induced
latency)
MIC90 (μg ml
−1)
BBZ5 >64 0.06 0.125 0.5 0.03–0.06 0.125 16 8
BBZ8 >64 >64 >128 >128 >32 >32 >16 NA
BBZ9 >64 0.06 0.03–0.06 0.06 0.06 0.06 1 2
SMT19969 >16 NA >128 >128 0.06–0.125 0.125 NA NA
Response to BBZ5 and BBZ9
Bacteriostatic/bacteriocidal? Bacteriostatic Bactericidal Bactericidal NA
Morphological response Filamentation Swelling Filamentation NA
Topoisomerase inhibition IC50 (μM) Escherichia coli Staphylococcus aureus Clostridium difficile Mycobacterium tuberculosis
DNA gyrase supercoiling
BBZ5 >50 0.3 8.4 11.3
BBZ8 >50 8.8 NA 29
BBZ9 >50 5.6 NA 2
SMT19969 >50 >50 >50 ND
Topoisomerase IV decatentation
BBZ5 8.0 15.5 NA NA
BBZ8 >50 70.3 NA NA
BBZ9 >50 50.9 NA NA
SMT19969 >50 >50 NA NA
Topoisomerase IV relaxation
BBZ5 6.5 NA NA NA
BBZ8 >50 NA NA NA
BBZ9 >50 NA NA NA
SMT19969 NA NA NA NA
a Dale et al., to be published. b Reference 24. c Reference 23.
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View Article Onlinewith data on SMT19969. In terms of mechanism of action,
although this has not yet been definitively determined for
SMT19969, it is clear from the gyrase and other data that it
differs from the other BBZs and is for example not a gyrase
or topoisomerase inhibitor in C. difficile, nor does it bind to
duplex DNA. SMT19969 does not obey 4/5 of Lipinski's rules,
which is precisely why it looks to be such an effective drug
for C. difficile infections: as a consequence it is not orally bio-
available and is retained in the gut, in close physical proxim-
ity to C. difficile bacteria.
Summit Therapeutics has subsequently undertaken the
further development of the series leading to the advancement
of SMT19969 into current clinical trials in humans. This com-
pound shows exceptional selectivity and potency for the
bacterium27–29 and pre-clinical data indicated that it hasThis journal is © The Royal Society of Chemistry 2015remarkably low toxicity, which was confirmed by a Phase I
clinical trial in 2012. The trial found that the novel orally-
administered small-molecule antibiotic is selective for the
treatment of C. difficile infections and did not affect other
pathogens. It was announced in April 2013 that the Phase I
trial had been concluded, with very successful results. A
Phase 2 trial is currently underway in C. difficile patients and
initial results will become available in 2015. In July 2015 the
US Food and Drug Administration granted Fast Track desig-
nation to SMT19969 for the treatment of C. difficile.What does the BBZ story tell us about academic drug discovery?
One could argue that the discovery of SMT19969 was acciden-
tal, with the key events being the evaluation of the existing
BBZ compounds for anti-bacterial activity. However such
“accidents” do not occur randomly – they require that those
involved are smart enough to spot something of interest, wor-
thy of an investment in time and money. Similarly the initial
invention of the BBZ series by John Mann and Stephen
Neidle, even though it was initiated by a chance meeting, was
based on a great deal of prior knowledge of the structural fea-
tures of minor groove-binding agents. The BBZ compounds
came about, not because Mann and Neidle saw the project as
an opportunity to write a grant proposal, but simply because
they were enthused by the science and its possibilities, andMed. Chem. Commun., 2015, 6, 1420–1426 | 1425
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View Article Onlinethat they wished to work together on a project of mutual inter-
est. The fact that the original intent of creating novel DNA rec-
ognition units based on the BBZ scaffold has been superseded
by a quite distinct goal, of creating novel anti-infective agents,
is to our minds, a powerful argument for fostering basic sci-
ence and ensuring that opportunistic links are put in place to
assess the therapeutic potential of any outcomes.
All of this would not have come to a focus, and SMT19969
would not have existed without the involvement of a commer-
cial organisation, nimble enough to spot a potential opportu-
nity. Whether a larger organisation would have become
involved so quickly, or at all, is an interesting question (the
original patent assigned to Roche, was abandoned by them
before SMT19969 existed). Any early-stage therapeutic project
requires substantial funding in order to progress and the
Wellcome Trust's enthusiastic support via its Seeding Drug
Discovery Programme was crucial. It is notable that this sup-
port was not based on the normal requirement of a validated
target (as stated above the target(s) are still unclear), but on a
robust case focussed around unmet clinical need and the
properties of SMT19969 to effectively meet this need.
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